Special feature in the series "Drug Discovery Ecosystem
A New Map for Drug Discovery Together
New initiatives by industry, government, and academia are underway to strengthen Japan's drug discovery capabilities, including collaboration among companies at Shonan Eye Park, a new platform for industry-academia collaboration by AMED and the Pharmaceutical Cooperative Association, and startup support by the Ministry of Economy, Trade and Industry. We are beginning to see the shape of a drug discovery ecosystem that will come to fruition through an all-Japan approach.
From JPMA
The Future of the Pharmaceutical Industry
Chairman Ueno and President Kinoshita in conversation
Japan's pharmaceutical industry is now at a turning point, triggered by the reform of the drug price system. Chairman Ueno and President Kinoshita of the Pharmaceutical Manufacturers Association of Japan (PMAJ) passionately discussed the path to recovery of drug discovery capabilities, including strengthening research collaboration with academia, promoting cooperation with start-ups, and accelerating overseas expansion.
The Pharmaceutical Industry from a Factual Perspective
The Reality of Drug Research and Development as Seen in Data
New drug development requires a long period of time and huge investment. A comprehensive survey conducted by the Pharmaceutical Industry Policy Institute for the first time in 11 years reveals the reality of research and development. The results are rich in important implications for those of us working in the field of drug discovery.
Key words to keep in mind
First-in-Human Testing
Development of Implementation System
The "First-in-Human (FIH) Study" is the world's first study in which a drug is administered to humans. The establishment of a system to conduct this study will be a new turning point for drug development in Japan. We will look at the significance and prospects of this project, from the elimination of drug lag/loss to the creation of a drug discovery environment.
My Committee
vol.1 Public Relations Committee
The Pharmaceutical Manufacturers Association of Japan (PMAJ) has 12 committees and 6 specialized organizations. In this first issue, we focus on the Public Relations Committee, which was established in 1978, and look at the forefront of activities to communicate the "now" of the pharmaceutical industry to society and the thoughts of those who are responsible for these activities.
Topics
Introduction of various topics within the association
From expectations for strengthening drug discovery, to the development of regulatory science, to new developments in countermeasures against infectious diseases, to the possibilities of Life Course Immunization, we look at the key events held by the Pharmaceutical Manufacturers Association of Japan (PMAJ). From important conferences and forums held by the Pharmaceutical Manufacturers Association of Japan (PMAJ), we have learned about the latest trends surrounding the industry and the challenges we must face.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire